Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Proper subcellular localization is crucial for the functioning of biomacromolecules, including
proteins and RNAs. Nuclear transport is a fundamental cellular process that regulates the …

In lung and prostate adenocarcinomas, neuroendocrine (NE) transformation to an
aggressive derivative resembling small cell lung cancer (SCLC) is associated with poor …

Selinexor is an oral inhibitor of the nuclear export protein called Exportin 1 (XPO1) with
demonstrated antitumor activity in hematological and solid tumors. Selinexor, blocking …

Purpose Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor
proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells …

In this special edition update on soft tissue sarcomas (STS), we cover classifications,
emerging technologies, prognostic tools, radiation schemas, and treatment disparities in …

Simple Summary Liposarcoma is the most widespread soft-tissue sarcoma in adults. This
review summarizes the molecular genetics and epigenetics of the main liposarcoma …

Importance Treatment options for patients with unresectable and/or metastatic
dedifferentiated liposarcoma (DDLPS) are limited. New drugs are required. Objective To …

Abstract Background Selinexor (KPT‐330) is a potent inhibitor of exportin 1 (XPO1), in turn
inhibiting tumor growth. Selinexor enhances the antitumor efficacy of eribulin in triple …

As the world's first oral nuclear export inhibitor, selinexor is increasingly being used in
clinical applications for malignant tumors. However, there is no extensive exploration on …